Selective Inhibition of Aurora Kinase A by AK-01/LY3295668 Attenuates MCC Tumor Growth by Inducing MCC Cell Cycle Arrest and Apoptosis

• Published in: Cancers 2021-07, Vol.13 (15), p.3708
• Main Authors: Das, Bhaba K, Kannan, Aarthi, Nguyen, Quy, Gogoi, Jyoti, Zhao, Haibo, Gao, Ling
• Format: Article
• Language: English
• Subjects: Animal models; Antibodies; Apoptosis; Aurora kinase; Cancer; Cancer immunotherapy; Cell culture; Cell cycle; Cell growth; Cell survival; Immune checkpoint inhibitors; Immune system; Immunotherapy; Kinases; Laboratory animals; Medical prognosis; Melanoma; Mutation; Patients; Skin cancer; Therapeutic targets; Toxicity; Tumor suppression; Tumors; Xenografts
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers13153708

Merkel cell carcinoma (MCC) is an often-lethal skin cancer with increasing incidence and limited treatment options. Although immune checkpoint inhibitors (ICI) have become the standard of care in advanced MCC, 50% of all MCC patients are ineligible for ICIs, and amongst those treated, many patients develop resistance. There is no therapeutic alternative for these patients, highlighting the urgent clinical need for alternative therapeutic strategies. Using patient-derived genetic insights and data generated in our lab, we identified aurora kinase as a promising therapeutic target for MCC. In this study, we examined the efficacy of the recently developed and highly selective AURKA inhibitor, AK-01 (LY3295668), in six patient-derived MCC cell lines and two MCC cell-line-derived xenograft mouse models. We found that AK-01 potently suppresses MCC survival through apoptosis and cell cycle arrest, particularly in MCPyV-negative MCC cells without RB expression. Despite the challenge posed by its short in vivo durability upon discontinuation, the swift and substantial tumor suppression with low toxicity makes AK-01 a strong potential candidate for MCC management, particularly in combination with existing regimens.